Shares of NewLink Genetics Corporation (NASDAQ:NLNK) shot up 29.9% during trading on Friday . The stock traded as high as $19.30 and last traded at $17.67. 31,298,680 shares were traded during trading, an increase of 2,485% from the average session volume of 1,210,950 shares. The stock had previously closed at $13.60.

Several brokerages have commented on NLNK. Jefferies Group LLC set a $7.00 target price on shares of NewLink Genetics Corporation and gave the stock a “hold” rating in a report on Friday, August 25th. ValuEngine upgraded shares of NewLink Genetics Corporation from a “strong sell” rating to a “sell” rating in a report on Thursday. Zacks Investment Research upgraded shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Wednesday, June 7th. Robert W. Baird downgraded shares of NewLink Genetics Corporation from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $25.00 to $8.00 in a report on Thursday, June 8th. Finally, Cantor Fitzgerald set a $26.00 target price on shares of NewLink Genetics Corporation and gave the stock a “buy” rating in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. NewLink Genetics Corporation presently has an average rating of “Buy” and an average target price of $20.50.

The firm has a 50-day moving average of $7.51 and a 200 day moving average of $12.84. The firm’s market capitalization is $519.87 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last issued its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.21. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. The company had revenue of $10.37 million for the quarter, compared to analyst estimates of $2.65 million. Equities analysts predict that NewLink Genetics Corporation will post ($2.82) earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company raised its position in shares of NewLink Genetics Corporation by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 556 shares during the period. State Street Corp raised its position in shares of NewLink Genetics Corporation by 1.2% during the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after purchasing an additional 4,630 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of NewLink Genetics Corporation during the second quarter worth approximately $286,000. PDT Partners LLC raised its position in shares of NewLink Genetics Corporation by 160.2% during the second quarter. PDT Partners LLC now owns 115,795 shares of the biotechnology company’s stock worth $851,000 after purchasing an additional 71,295 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of NewLink Genetics Corporation by 40.2% during the second quarter. Dimensional Fund Advisors LP now owns 120,767 shares of the biotechnology company’s stock worth $888,000 after purchasing an additional 34,624 shares during the period. 54.78% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “NewLink Genetics Corporation (NLNK) Shares Up 29.9%” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/08/newlink-genetics-corporation-nlnk-shares-up-29-9.html.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.